Lentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts

被引:23
作者
Durual, S.
Rideau, A.
Ruault-Jungblut, S.
Cossali, D.
Beris, P.
Piguet, V.
Matthes, T. [1 ]
机构
[1] Univ Hosp Geneva, Div Hematol, Geneva, Switzerland
[2] Univ Hosp Geneva, Div Clin Pathol, Geneva, Switzerland
[3] Univ Hosp Geneva, Dept Dermatol & Venerol, Geneva, Switzerland
关键词
PU.1; acute myeloid leukemia; lentivectors; transcription factors; hematopoiesis;
D O I
10.1038/sj.leu.2404645
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PU.1, a transcription factor of the ETS family, plays a pivotal role in normal hematopoiesis, and particularly in myeloid differentiation. Altered PU.1 function is possibly implicated in leukemogenesis, as PU. 1 gene mutations were identified in some patients with acute myeloid leukemia (AML) and as several oncogenic products (AML1-ETO, promyelocytic leukemia-retinoic acid receptor alpha, FMS-like receptor tyrosine kinase 3 internal tandem duplication) are associated with PU.1 downregulation. To demonstrate directly a role of PU.1 in the blocked differentiation of leukemic blasts, we transduced cells from myeloid cell lines and primary blasts from AML patients with a lentivector encoding PU.1. In NB4 cells we obtained increases in PU.1 mRNA and protein, comparable to increases obtained with all-trans retinoic acid-stimulation. Transduced cells showed increased myelomonocytic surface antigen expression, decreased proliferation rates and increased apoptosis. Similar results were obtained in primary AML blasts from 12 patients. These phenotypic changes are characteristic of restored blast differentiation. PU.1 should therefore constitute an interesting target for therapeutic intervention in AML.
引用
收藏
页码:1050 / 1059
页数:10
相关论文
共 32 条
[1]   PU. 1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain [J].
Cook, WD ;
McCaw, BJ ;
Herring, C ;
John, DL ;
Foote, SJ ;
Nutt, SL ;
Adams, JM .
BLOOD, 2004, 104 (12) :3437-3444
[2]   Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBP ratio and granulocyte colony-stimulating factor [J].
Dahl, R ;
Walsh, JC ;
Lancki, D ;
Laslo, P ;
Iyer, SR ;
Singh, H ;
Simon, MC .
NATURE IMMUNOLOGY, 2003, 4 (10) :1029-1036
[3]   Regulation of B lymphocyte and macrophage development by graded expression of PU.1 [J].
DeKoter, RP ;
Singh, H .
SCIENCE, 2000, 288 (5470) :1439-1441
[4]   Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia:: a study of the AML Study Group Ulm (AMLSG ULM) [J].
Döhner, K ;
Tobis, K ;
Bischof, T ;
Hein, S ;
Schlenk, RF ;
Fröhling, S ;
Döhner, H .
BLOOD, 2003, 102 (10) :3850-3850
[5]   PU.1 phosphorylation correlates with hydroquinone-induced alterations in myeloid differentiation and cytokine-dependent clonogenic response in human CD34+ hematopoietic progenitor cells [J].
Gross, S. A. ;
Zheng, J. H. ;
Le, A. T. ;
Kerzic, P. J. ;
Irons, R. D. .
CELL BIOLOGY AND TOXICOLOGY, 2006, 22 (04) :229-241
[6]  
HOHAUS S, 1995, MOL CELL BIOL, V15, P5830
[7]  
Iida H, 2000, INT J HEMATOL, V71, P153
[8]   Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? [J].
Lamandin, C ;
Sagot, C ;
Roumier, C ;
Lepelley, P ;
De Botton, S ;
Cosson, A ;
Fenaux, P ;
Preudhomme, C .
BLOOD, 2002, 100 (13) :4680-4681
[9]  
LANOTTE M, 1991, BLOOD, V77, P1080
[10]   Optimized lentiviral transduction of erythroid precursors from healthy adults and patients with myelodysplastic syndromes [J].
Matthes, TW ;
Kindler, V ;
Leuba, F ;
French, LE ;
Chapuis, B ;
Beris, P ;
Piguet, V .
LEUKEMIA, 2002, 16 (07) :1319-1323